Pulses - Orlando
2025-03-07 - 2025-03-09 | Omni Orlando Resort at ChampionsGate, 1500 Masters Blvd, Championsgate, FL, United States
This in-depth training course offers a certificate of completion and features lectures and over 2 hours of hands-on training delivered by Clinical TMS Society renowned clinicians, engineers, and researchers and some special guests. Attendees will receive current, historical, and practical knowledge for treating patients with TMS based on the best evidence.
Register Now

Date/Time: Friday March 7, 2025 (4pm ET) - Sunday, March 9, 2025 (3pm ET) (time is subject to change)
Location: The Omni Orlando Resort at ChampionsGate: 1500 Masters Blvd, ChampionsGate, FL 33896
The program includes:
1. An introduction to the history of and basic scientific principles of TMS by Professor Anthony Barker, who designed the first-ever TMS machine in 1985;
2. A review of the clinical studies that serve as the foundation for treatment of TMS for depression, as well as clinically applicable research and current important studies;
3. Four lectures on the practical administration of TMS for patients, including practice setup to patient dosing, scheduling, and management;
4. A review of protocols for TMS: high frequency, theta-burst, low frequency, bilateral, alternative brain targets, rescue treatment, maintenance treatment;
5. A revised lecture on TMS risk and their prevention and management, including seizure protocol review;
6. Hands-on training on coil location placement & motor threshold determination with multiple TMS devices;
7. A review of promising indications beyond depression, including, obsessive compulsive disorder, smoking cessation, migraine, post-traumatic stress disorder, anxiety, and pain; and An extended Q & A Panel with all PULSES faculty and special guests.
8. After completion of the course, the clinician will have obtained a historical, current, and practical knowledge of the scientific basis for treating psychiatric patients with TMS.
Attendees will also have the ability to participate in an interactive Q&A Panel with Pulses faculty. Those who complete the course are awarded a certificate of completion.
Cancellation Policy:
Conference registration cancellations must be received in writing on or before February 1, 2025, to receive a refund minus a $100.00 administration fee.
Conference registration may not be transfered to a future conference.
No refunds will be issued for cancellations received after February 1, 2025.
In the event CTMSS must cancel the conference due to unforeseen circumstances, CTMSS will refund the cost of registration. However, CTMSS does not assume responsibility for any additional costs, charges, or expenses; to include, charges made for travel and lodging

Minding Your Own TMS Business
2025-03-25 20:00 - 21:00 (America/New_York)
📅 March 25, 2025
📍 Virtual
Moderated by Dr. Linda Carpenter, with an all-female panel, including current CTMSS President, Dr. Martha Koo, Dr. Rebecca Allen, Dr. Carlene MacMillan and Dr. Kristin Raj.
$25 Donation. All proceeds benefit the Patient Assistance Fund.
REGISTER NOW >

Grand Round Webinar: Research 101: What data can I report from my TMS practice, and how can I report it?
2025-05-06 20:00 - 21:00 (America/New_York) | Zoom
> >Register Now <<
Join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: "Research 101: What data can I report from my TMS practice, and how can I report it?"
Speaker: Andrew F. Leuchter, MD
rTMS is a rapidly growing area of clinical practice. Many practitioners have created innovative approaches to treatment, observed novel findings that could help improve outcomes, or discovered new potential indications for rTMS treatment. This presentation will review the types of data that can be reported in the scientific and clinical literature, how to approach creating a report, and how to find the right "home" for publication.
Key learning objectives include:

Present goals of naturalistic research in TMS practice.
Discuss different types of research report formats.
Consider what constitutes a meaningful contribution to the literature.

Take advantage of our live Q&A session at the conclusion of the webinar.
One CME credit is available. CE Language

*Registered attendees will receive access to the on-demand video recording by Friday, May 9, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - May 6, 2025 at 8:00pm ET | 5:00pm PT
UK- May 7, 2025 at 1:00am BST
Australia- May 7, 2025 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
All Grand Rounds are recorded and available On-Demand. Recordings are available by the Friday after the live event.
> >Register Now <<
About the Speaker: Andrew F. Leuchter, MD
Andrew F. Leuchter, MD, is a Distinguished Professor of Psychiatry and Director of the Neuromodulation Division at UCLA. An expert on the treatment of mood disorders, Dr. Leuchter directs the Transcranial Magnetic Stimulation (TMS) Clinical and Research Service. This is one of
the largest academic TMS program in the country and treats patients with depression, OCD, pain, tinnitus, and other neuropsychiatric illness. His research aims to develop novel treatment strategies and predict which treatments are most likely to benefit individual patients.
Dr. Leuchter has authored over 200 scientific articles on topics including neuromodulation for the treatment of depression, EEG biomarkers to guide treatment of neuropsychiatric illness, and theories of antidepressant action. He teaches internationally on TMS and other neuromodulation methods, and received the 2019 Outstanding Research Mentor Award from the Semel Institute.
Andrew F. Leuchter, MD, is a Distinguished Professor of Psychiatry at the Semel Institute for Neuroscience and Human Behavior, and Director of the Neuromodulation Division at the Semel Institute. An expert on the treatment of mood disorders, Dr. Leuchter directs the Transcranial Magnetic Stimulation (TMS) Clinical and Research Service. This is one of the largest academic TMS programs, performing clinical treatment and translational research across campuses throughout Los Angeles. The dual mission of the Division is to provide care for patients with depression, chronic pain, OCD, tinnitus, and other difficult-to-treat neuropsychiatric illness, as well as enhancing treatment effectiveness, as well as clinical trials to improve treatment of depression, Post-Traumatic Stress Disorder (PTSD), and Attention-Deficit/Hyperactivity Disorder (ADHD). Dr. Leuchter’s research aims to develop novel treatment strategies and uses brain-imaging techniques, such as quantitative electroencephalography (qEEG) and magnetic resonance imaging (MRI) to examine brain function and predict which treatments are most likely to benefit individual patients.
> >Register Now <<

FACTMS: Future Directions in TMS Therapy
2025-06-12 20:00 - 22:00 UTC | San Diego
Future Directions in TMS Therapy
📅 June 12, 2025
🕗 8:00 – 10:00 PM PT
📍 Sheraton San Diego Hotel & Marina, Marisol Room

Dr. Siddiqi Dr. Wiliams

Join FACTMS for a wonderful event during the Clinical TMS Society Annual Meeting. The evening will feature the first Ad Astra Award presentation to Dr. Nolan Williams and Dr. Shan Siddiqi. In addition to an inspiring presentation, enjoy hors d’oeuvres, specialty cocktails and a popular silent auction with vacation packages, TMS memorabilia and other exciting items.

All proceeds benefit the Bob Sammons Clinical TMS Research Grant.
LEARN MORE >

Grand Rounds Webinar: Advocating for TMS Coverage: An International Perspective
2025-07-01 20:00 - 21:00 (America/New_York) | Zoom
> >Register Now <<
Join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Advocating for TMS Coverage: An International Perspective
Speakers: Carlene MacMillan, MD, FCTMSS, DFAACAP and Shelly Weiss Lahn, BS, CRA
Join leaders from the Clinical TMS Society for a global exploration of insurance coverage for Transcranial Magnetic Stimulation. This session will share insights from a survey of international CTMSS members, expert interviews, and a review of global reimbursement models. Learn how clinicians around the world are successfully advocating for broader TMS access—and gain practical strategies to advance coverage in your own region.
Key learning objectives include:

Identify key differences in insurance coverage policies for TMS across international healthcare systems.
Analyze effective advocacy strategies used by clinicians and organizations to expand TMS access globally.
Apply insights from international case studies to develop tailored approaches for improving TMS coverage in participants' local contexts.

Take advantage of our live Q&A session at the conclusion of the webinar.
One CME credit is available. CE Language
*Registered attendees will receive access to the on-demand video recording by Monday, July 7, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - July 1, 2026 at 8:00pm ET | 5:00pm PT
UK- July 2, 2026 at 1:00am BST
Australia- July 2, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speakers
Carlene MacMillan MD, FCTMSS, DFAACAP
Dr. Carlene MacMillan is the co-chair of the Clinical TMS Society Insurance Committee and the Member-at-Large on the Executive Committee. She is also on the board of the Foundation for the Advancement of Clinical TMS. She is board-certified in adult and child psychiatry. Dr.MacMillan is the Chief Product Officer at Radial, a network of interventional practices.

Shelly Weiss Lahn BS, CRA
Shelly Weiss Lahn is the co-chair of the Clinical TMS Society Insurance Committee. She is the CEO of Neuro Wellness TMS Centers of America in Coral Springs, Florida and the owner of Overseas Referral Network of America, an International Medical Concierge Service.

Neuroimaging to Enhance Precision in Clinical Trials
2025-08-05 20:00 - 21:00 UTC
> >Register Now <<
Join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Neuroimaging to Enhance Precision in Clinical Trials
Speaker: Aristotle Voineskos, MD, PhD, FRCPC
This Grand Rounds explores how the upcoming use of neuroimaging is being used to better direct clinical care. This session discusses precision medicine, implementation strategies, and learning health systems to deliver more targeted, evidence-based treatments. The content is grounded in high-impact, peer reviewed literature to ensure scientific rigor.
Key learning objectives include:

Design considerations for imaging in trials.
Considerations for precision imaging in trials.
Emerging applications of precision imaging in trials.

Take advantage of our live Q&A session at the conclusion of the webinar.
One CME credit is available. CE Language
*Registered attendees will receive access to the on-demand video recording by Monday, August 11, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - August 5, 2026 at 8:00pm ET | 5:00pm PT
UK- August 6, 2026 at 1:00am BST
Australia- August 6, 2025 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker
Aristotle Voineskos, MD, PhD, FRCPC
Dr. Aristotle Voineskos is the Senior Vice President, Research and Science & Director of the Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health (CAMH). At both CAMH and the University Health Network (UHN), he serves as the joint Vice President for the CAMH-UHN Partnership. Dr. Voineskos earned his MD and PhD at the University of Toronto, and completed a research fellowship at Brigham and Women’s Hospital, Harvard Medical School. Dr. Voineskos is a Professor of Psychiatry at the
Temerty Faculty of Medicine. He is an internationally recognized researcher, physician, and leader, who has been dedicated to helping people suffering from severe mental illness and brain disorders.
Dr. Voineskos has served in progressive clinical and research leadership roles across his career. In these roles, he has significantly improved access to care, reduced wait times, and implemented and scaled evidence-based care models across the health system. Most recently as Vice President Research at CAMH, he helped grow the research enterprise substantially, via key pillars of equity, training and evaluation, clinical-research integration, open science, digital transformation, and sustainability. He is known for driving innovation and enhancing team performance. As joint Vice President of the CAMH-UHN Partnership, he helps lead the work across executive teams to deliver comprehensive physical and mental health care for patients, and accelerate advancements in brain health sciences.
Dr. Voineskos has published over 300 papers many of which are in the leading journals of psychiatry, neurology, medicine, and neuroscience. He has won numerous awards for his research and mentorship including the A.E. Bennett Award for Clinical/Translational Research from the Society of Biological Psychiatry (SOBP) in 2022 and the Joel Elkes Research Award from the American College of Neuropsychopharmacology (ACNP) in 2024.

TMS for Stroke Rehabilitation
2025-09-02 20:00 - 21:00 UTC
> >Register Now <<
Join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: TMS for Stroke Rehabilitation
Speaker: Dylan J. Edwards, PhD
The first demonstration of transcranial magnetic stimulation (TMS) occurred nearly 40 years ago, and it showed that TMS could readily activate the human cortex without sophisticated targeting. However, as a tool to probe and modify cortical function, TMS has historically been limited by imprecise targeting. With new advances, including neuronavigation and contemporary modeling of cortical electric field distribution, we are now able to use TMS to examine the detailed functional organization of the primary motor cortex, as well as how the cortex is reorganized after the brain is lesioned. In research to date, patient responses to TMS have been variable, and inaccurate targeting may be a key factor contributing to the high variability in response rate to repetitive TMS (rTMS) interventions. The precision of TMS targeting will be discussed in the context of neurorehabilitation and motor recovery.
Key learning objectives include:

Describe the rationale for using TMS in recovery of motor function after damage to the cortico-spinal tract such as in stroke or spinal cord injury.
Describe the benefit of electric field modeling in estimating optimal treatment intensity.
State the principal result of at least one rTMS/neurorecovery RCT over the past decade.

Take advantage of our live Q&A session at the conclusion of the webinar.
One CME credit is available. CE Language
*Registered attendees will receive access to the on-demand video recording by Friday, September 8, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - September 2, 2025 at 8:00pm ET | 5:00pm PT
UK- September 3, 2025 at 1:00am BST
Australia- September 3, 2025 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Dylan J. Edwards, PhD
Dr. Dylan J. Edwards is the Nancy Wachtel Shrier Director of Jefferson Moss Rehabilitation Research Institute, Director of the Human Motor Recovery Laboratory at the Institute, Professor in the Department of Rehabilitation Medicine at The Sidney Kimmel Medical College at Thomas Jefferson University, and Adjunct Professor of Neuroscience and Director of the NeuroRehabilitation and Robotics Laboratory at Edith Cowan University. He is dedicated to translating basic science findings in neurologically healthy people to develop and evaluate novel, clinically-relevant approaches for neurological assessment and neurorehabilitation in stroke and spinal cord injury using non-invasive stimulation, neuromodulation, robotics, combinatorial therapies, neuroimaging, and telerehabilitation.

PULSES
2025-09-26 - 2025-09-28
This in-depth training course offers a certificate of completion and features lectures and over 3 hours of hands-on training delivered by Clinical TMS Society renowned clinicians, engineers, and researchers and some special guests. Attendees will receive current, historical, and practical knowledge for treating patients with TMS based on the best evidence.
The program includes:

An introduction to the history of and basic scientific principles of TMS by Professor Anthony Barker, who designed the first-ever TMS machine in 1985;
A review of the clinical studies that serve as the foundation for treatment of TMS for depression, as well as clinically applicable research and current important studies;
Four lectures on the practical administration of TMS for patients, including practice setup to patient dosing, scheduling, and management;
A review of protocols for TMS: high frequency, theta-burst, low frequency, bilateral, alternative brain targets, rescue treatment, maintenance treatment;
A lecture on TMS risks and their prevention and management, including seizure protocol review;
Hands-on training on targeting, coil placement, and motor threshold determination with multiple TMS devices;
A review of promising indications beyond depression, including, obsessive compulsive disorder, smoking cessation, migraine, post-traumatic stress disorder, anxiety, and pain; and
A special track with lectures and hands-on training tailed for TMS technicians; and
An extended Q & A Panel with all PULSES faculty and special guests.

After completion of the course, the clinician will have obtained a historical, current, and practical knowledge of the scientific basis for treating psychiatric patients with TMS. Technicians will have additional skills needed for daily patient assessment, monitoring, and administration of stimulation.
Attendees will also have the ability to participate in an interactive Q&A Panel with Pulses faculty. Those who complete the course are awarded a certificate of completion.
Date/Time: 26-28 September 2025 | 9:00 am to 6:00 pm (PT) (time is subject to change)
Location: Providence, Rhode island | Butler Hospital | 345 Blackstone Blvd, Providence, RI 02906
CLICK HERE FOR MORE INFORMATION

The RECOVER Trial of Vagus Nerve Stimulation in Markedly Treatment-Resistant Depression: Critical Findings, Lessons Learned, Future Directions
2025-10-07 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Scott T. Aaronson, MD
The RECOVER study is a large randomized sham controlled study of vagus nerve stimulation in markedly treatment resistant depression involving 1000 participants. The first papers for the unipolar cohort have been published and submitted to the Centers for Medicare and Medicaid for re-consideration for coverage. This presentation will review the extensive database, the important lessons learned about studying severely treatment resistant depression and anticipate possible future availability of this novel therapy.
Key learning objectives include:

Identify how to improve assessment of patient outcomes in severely treatment resistant depression.
Recognize patient presentations with increased likelihood of benefit from vagus nerve stimulation.
Describe the proposed mechanism of action for vagus nerve stimulation in treating depression.

Take advantage of our live Q&A session at the conclusion of the webinar.
One CME credit is available. CE Language
*Registered attendees will receive access to the on-demand video recording by Friday, October 10, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - October 7, 2025 at 8:00pm ET | 5:00pm PT
UK- October 8, 2025 at 1:00am BST
Australia- October 8, 2025 at 10:00am AEDT
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Scott T. Aaronson, MD
Dr. Scott Aaronson is a thought leader in the areas of biological psychiatry, diagnosis, and the integration of somatic and psychological therapies. He is an adjunct professor of psychiatry at the University of Maryland School of Medicine, distinguished life fellow of the American Psychiatric Association, and is a fellow of the American College of Psychiatrists, the Clinical TMS Society and the American Society for Clinical Psychopharmacology. Dr. Aaronson also serves on the board of the American Society for Clinical Psychopharmacology. He graduated with honors from Harvard Medical School and completed his psychiatric residency at McLean Hospital.
Dr. Aaronson is the Chief Science Officer for the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt. He has been involved with the development of new strategies to alleviate the symptoms in treatment resistant mood disorders, and has published numerous articles on his research including pivotal studies in the use of devices—Transcranial Magnetic Stimulation (TMS), Vagus Nerve Stimulation (VNS) and psychedelics in the treatment of severe refractory mood disorders. His paper on a five year observational study of VNS in treatment resistant depression published in 2017 in the American Journal of Psychiatry led to the Centers for Medicare and Medicaid supporting a randomized clinical trial of VNS in unipolar and bipolar depression through their Coverage with Evidence Development Program. He is on the committee that developed this study and is now in the process of publishing the results from the unipolar arm in a series of articles.

First Principles of TMS Induced Synaptic Plasticity and Potential Impact on Clinical Outcomes
2025-12-02 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Alex McGirr, MD, PhD, FRCPC
Transcranial magnetic stimulation is delivered in patterns of pulses that are informed by pre-clinical electrophysiology to induce changes at the level of the synapse. Our delivery of this treatment is agnostic to two major confounds that influence the ability of synaptic weights to change in response to stimulation:
a) disease processes limiting plasticity
b) concurrent pharmacology
This grand rounds will review clinically relevant implications of these, and the emerging space using pharmacological adjuvants to enhance the effects of stimulation and its relation to clinical outcomes.
Key learning objectives include:

Explain the mechanisms of transcranial magnetic stimulation (TMS), inclucing how pulse patterns influence synaptic plasticity and the role of electrophysiological principles.
Identify factors that affect synaptic responsiveness to TMS, such as disease-related limitations in plasticity and the impact of concurrent pharmacological treatments.
Discuss the clinical implications of combining TMS with pharmacological adjuvants, including how these interactions can enhance stimulation effects and influence clinical outcomes.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, December 5, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - December 2, 2025 at 8:00pm ET | 5:00pm PT
UK- December 3, 2025 at 1:00am GMT
Australia- December 3, 2025 at 12:00pm AEDT
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Alexander McGirr, MD, PhD, FRCPC
Dr. Alexander McGirr is a psychiatrist and clinician scientist at the University of Calgary, Canada. He trained across major Canadian institutions, including
McGill University (undergraduate and masters of neuroscience), the University of Toronto (MD), and the University of British Columbia (psychiatry residency
and PhD neuroscience). His clinical work and research focuses on mood disorders, circuit dissection, and non-invasive neurostimulation as both a means
of probing the brain and inducing changes in neural circuits underlying pathology. Although his research program includes both basic science and
clinical arms, the focus of this ground rounds will be clinical.

Single-Day Regimens for TMS: Recent Progress and Open Questions *Free Session*
2026-01-06 20:00 - 21:00 UTC
Kick off the year with complimentary Grand Rounds!
> >Register Now <<
Speaker: Jonathan Downar, MD, PhD, FRCPC
Improving access to TMS is a priority for practitioners and patients alike. Multi-day treatment protocols pose a significant logistical barrier to access for many patients, especially those in remote areas.
Recently, proof-of-concept studies have begun to investigate the effectiveness of single-day TMS regimens. Here we review the development of single-day TMS protocols, along with relevant studies on potential mechanisms. We consider new data on the outcomes of single-day TMS in various applications. We examine possible refinements of the approach to improve practicality, tolerability, and effectiveness. We consider important outstanding questions requiring future research on this novel but potentially quite impactful approach to TMS treatment.
Key learning objectives include:

Review rationale, mechanisms, and history of development of single-day TMS protocols.
Review recent progress in refining single-day TMS protocols and comparative outcomes vs. conventional once-daily protocols.
Review outstanding questions facing future developments and refinement of single-day TMS protocols.

Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, January 9, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - January 6, 2026 at 8:00pm ET | 5:00pm PT
UK- January 7, 2026 at 1:00am GMT
Australia- January 7, 2026 at 12:00pm AEDT
Cost:
Member: FREE
Trainee Member: FREE
Non-Member: FREE
*CME not available for this session.
> >Register Now <<
About the Speaker

Jonathan Downar, MD, PhD, FRCPC
Dr Jonathan Downar is an Adjunct Professor in the Department of Psychiatry and Institute of Medical Science at the University of Toronto. He holds a clinical appointment at the Centre for Addiction and Mental Health in Toronto. He holds a PhD in functional neuroimaging from the University of Toronto, trained in medicine at the University of Calgary, and completed his psychiatry residency at the University of Toronto.
Dr Downar has published over 180 peer-reviewed articles on TMS and brain imaging, in journals including Lancet, JAMA Psychiatry, Nature Medicine, Nature Neuroscience, and Brain Stimulation. He is the senior author of the THREE-D study, a major Canadian TMS study published in Lancet in 2018 that demonstrated that TMS treatments could be reduced from 38 min sessions to 3 minute sessions with no loss of efficacy. He has also pioneered the use of novel TMS protocols including dorsomedial TMS and orbitofrontal TMS in depression and in other clinical disorders.
He is currently working to develop novel protocols that improve the practicality and economics of TMS, with the goal of achieving cost parity with pharmacotherapy and universal access to this powerful treatment.

TMS for Schizophrenia
2026-02-03 20:00 - 21:00 (Asia/Dubai)
> >Register Now <<
Speaker: Roscoe Brady, PhD, MD
In this presentation we will review the use of TMS for treating symptoms of schizophrenia as well as its use as a research tool to understand schizophrenia pathophysiology. We will discuss symptoms such as medication refractory hallucinations, negative symptoms, and cognitive dysfunction. We will review different approaches including targets derived from both structural and functional neuroanatomy. Finally, we will talk about future directions in treatment including the use of TMS for schizophrenia related comorbidity.
Key learning objectives include:

Summarize the history of TMS trials for medication resistant symptoms of schizophrenia.
Describe how TMS is used as a research tool for understanding schizophrenia pathology.
Describe future directions for TMS trials both for treating schizophrenia symptoms as well as schizophrenia related comorbidity.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, February 6, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - February 3, 2026 at 8:00pm ET | 5:00pm PT
UK- February 4, 2026 at 1:00am GMT
Australia- February 4, 2026 at 12:00pm AEDT
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Roscoe Brady
Roscoe Brady MD, PhD is a board-certified psychiatrist and neuroscientist. He is the Vice-Chair for Research in the Department of Psychiatry at Beth Israel Deaconess Medical Center and an Associate Professor at Harvard Medical School. He is also the director of the Research Concentration in the Beth Israel Deaconess Medical Center Harvard Psychiatry Residency Training Program. He is the recipient of the Jonathan F. Borus Outstanding Early Educator Award and Stuart T. Hauser Mentorship Award from Harvard Medical School. His research focus is developing neuromodulation treatments for medication resistant symptoms of psychotic disorders. He is the Principal Investigator of multiple NIMH R01 funded clinical trials.

Accelerated TMS for Depression: Does Imaging Matter?
2026-03-03 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Joseph J. Taylor, MD, PhD
Neuroimaging is common in psychiatric research but rarely applied in psychiatric practice, even for brain stimulation treatments like transcranial magnetic stimulation (TMS). Recently, neuroimaging was used to target TMS during a condensed or “accelerated” treatment protocol. Known as Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), this intervention resulted in rapid and substantial antidepressant benefits. However, it remains unclear if neuroimaging is necessary for the rapid and substantial antidepressant benefits of accelerated TMS. This question is important to answer because neuroimaging adds cost and complexity to TMS. Here, we will present data from the first head-to-head trial of accelerated TMS with and without imaging guidance for treatment-resistant depression.
Key learning objectives include:

Describe the development of accelerated TMS.
Outline the five ways that the Cole et al protocol (branded SAINT) differs from conventional iTMS.
Summarize the results of this trial comparing imaging-versus scalp-based targeting of accelerated TMS.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, March 6, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - March 3, 2026 at 8:00pm ET | 5:00pm PT
UK- March 4, 2026 at 1:00am GMT
Australia- March 4, 2026 at 12:00pm AEDT
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Joseph J. Taylor, MD, PhD
Dr. Taylor is an Assistant Professor of Psychiatry at Harvard Medical School. At Brigham and Women’s Hospital, he is the Medical Director of TMS and the Director of Clinical Trials in the Center for Brain Circuit Therapeutics, the Director of the Interventional Psychiatry Research Program, and the Associate Program Director and Research Track Co-Director of the Psychiatry Residency Program. Dr. Taylor’s has expertise in interventional psychiatry, an emerging subspecialty in which procedural treatments are used for psychiatric illnesses that have not improved with routine psychotherapy and medications. Most of his research focuses on deriving and testing brain circuit targets for brain stimulation or neurosurgical ablation. Throughout his career, Dr. Taylor has received funding from the Howard Hughes Medical Institute, the National institutes of Health, the Sidney R. Baer, Jr. Foundation, the Baszucki Group, the Brain and Behavioral Research Foundation, Mass General Brigham, and Harvard Medical School.

CTMSS Training Singapore: PULSES & Pain Academy
2026-03-07 - 2026-03-08

Marketing & Promotion of Off-Label Uses of Repetitive TMS Treatment (rTMS)
2026-04-07 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Lindsay Oberman, PhD
This talk will review the Pro’s and Cons of off-label use of TMS. Dr. Oberman will then discuss the FDA clearance process and what indications are considered “off-label”. Finally, she will discuss the legal and ethical considerations for marketing and promoting off-label uses of TMS.
Key learning objectives include:

Gain awareness of what indications are "on label" versus "off label."
Gain awareness of federal regulations regarding marketing and promotion of FDA cleared devices.
Gain understanding of ethical considerations regarding marketing and use of rTMS off-label.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, April 10, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - April 7, 2026 at 8:00pm ET | 5:00pm PT
UK- April 8, 2026 at 1:00am BST
Australia- April 8, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Lindsay Oberman, PhD
Dr. Lindsay Oberman received her PhD from UCSD in Experimental Psychology in 2007. Since that time, she has published over 80 peer-reviewed articles. She has gained international attention for pioneering the use of Repetitive Transcranial Magnetic Stimulation (rTMS) in complex neurodevelopmental and neuropsychiatric disorders including autism, mood disorders, and traumatic brain injury. Dr. Oberman’s research involves the use of an experimental therapeutics approach applying neuroimaging and neurophysiological measures to identify dysfunctional neural circuitry associated with specific transdiagnostic behavioral domains such as mood regulation, sensory processing, social cognition, and executive functioning across disorders. In doing so, she is able to develop novel individualized rTMS treatment protocols that are informed by functional brain network organization. She is currently a Staff Scientist and Directs the Developmental Clinical Neurophysiology and Neurostimulation Research Program within the National Institute of Mental Health Intramural Research Program.

Combined Occipital and Trigeminal Afferent Stimulation for Depression: Findings from the Randomized Controlled Trial and the New ProLiv Home-Use Neuromodulation Device
2026-05-05 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Linda Carpenter, MD
Earlier this year, the FDA approved a novel home-use device for treatment of major depressive disorder in patients who have not responded to antidepressant medication. Available only with a prescription, Proliv™Rx is a wearable, at-home neurostimulation headset that uses non-invasive electrical pulses to stimulate the occipital and trigeminal nerves through surface electrodes.
Dr. Carpenter was the lead Principal Investigator for the large randomized controlled trial that generated efficacy and safety data for this device. She will present the data and describe how the ProLiv device will be used in future clinical practice.
Key learning objectives include:

Evaluate the clinical trial data supporting efficacy and safety of a new home-use device for treatment of Major Depressive Disorder (MDD).
Describe external combined occipital and trigeminal stimulation as a novel mechanism of action in the field of therapeutic neuromodulation.
Discuss how the ProLiv Rx device is incorporated into clinical care as an adjunct therapy for MDD.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, May 8, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - May 5, 2026 at 8:00pm ET | 5:00pm PT
UK- May 6, 2026 at 1:00am BST
Australia- May 6, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Linda Carpenter, MD
Dr. Carpenter has had nearly three decades of externally funded research focused on understanding biomarkers of early life stress and developing new treatments. She has expertise in clinical trials research involving pharmacotherapy and device-based neuromodulation treatments and has been PI on multiple industry- and NIH-funded randomized clinical trials, evaluating the safety and efficacy of both drug- and device-based therapies for depression and anxiety disorders. She has also conducted studies examining various mechanisms of therapeutic action and biomarkers of risk for psychiatric disorders.
For the past two decades, Dr. Carpenter's primary research focus has included therapeutic brain stimulation, and she has led numerous studies examining the efficacy, safety, and mechanisms of VNS, DBS, tDCS, TMS, and other neuromodulation devices in clinical populations.
Dr. Carpenter recently led the multi-center investigation of Proliv, a novel, FDA-cleared home-use device that delivers electrical trigeminal/occipital nerve stimulation for depression, and she is lead PI for a trial that uses fMRI-EEG-based neurofeedback for self-neuromodulation of a targeted depression circuit.
For the past 5 years Dr. Carpenter has also been developing methods for sustaining TMS antidepressant response over time with maintenance treatment and ecological momentary assessment.
Dr. Carpenter is the current Director of the CTMSS’s PULSES training course, and she serves on multiple other CTMSS committees.

PULSES Boston
2026-06-03 - 2026-06-04
Course Overview
This in-depth training course offers a Certificate of Completion and features lectures and over 3 hours of hands-on training delivered by Clinical TMS Society renowned clinicians, engineers, and researchers, along with special guests. Attendees will receive current, historical, and practical knowledge for treating patients with TMS based on the best available evidence.
The Program Includes:

A review of the clinical studies that serve as the foundation for treatment of TMS for depression, as well as clinically applicable research and current important studies.
Four lectures on the practical administration of TMS for patients, including practice setup to patient dosing, scheduling, and management.
A review of protocols for TMS: high frequency, theta-burst, low frequency, bilateral, alternative brain targets, rescue treatment, and maintenance treatment.
A revised lecture on TMS risks and their prevention and management, including seizure protocol review.
Hands-on training on coil location placement & motor threshold determination with multiple TMS devices.
A review of promising indications beyond depression, including, obsessive compulsive disorder, smoking cessation, migraine, post-traumatic stress disorder, anxiety, and pain.
An extended Q&A Panel with all PULSES faculty and special guests.

MORE DETAILS COMING SOON... Sign up for updates on when CTMSS opens PULSES registration...

Pain Academy Boston
2026-06-04

CTMSS 14th Annual Meeting
2026-06-04 - 2026-06-06

Clinical Outcomes Comparing MST and ECT in Patients with Depression
2026-07-07 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Daniel M. Blumberger, MD, MSc, FRCPC, FCTMSS
This presentation will present data from a large confirmatory efficacy trial of Magnetic Seizure Therapy in unipolar Depression and a smaller trial in patients with Bipolar Depression.
This treatment utilizes transcranial magnetic stimulation to induce a brief seizure with the hope of inducing similar clinical benefit without cognitive adverse effects of ECT.
Key learning objectives include:

Review the background and rationale for studying MST and ECT in the treatment of depression.
Understand the methodology and design of the CREST and CORRECT-BD trials.
Evaluate the efficacy, safety, tolerability, and clinical implications of MST as a potential treatment for TRD.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, July 10, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - July 7, 2026 at 8:00pm ET | 5:00pm PT
UK- July 8, 2026 at 1:00am BST
Australia- July 8, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Daniel M. Blumberger, MD, MSc, FRCPC, FCTMSS

Dr. Blumberger is a Senior Scientist in the Campbell Family Mental Health Research Institute at Centre for Addiction and Mental Health and a subspecialist in geriatric psychiatry. He is the Temerty Chair in Therapeutic Brain Intervention and the Scientific Director of the Temerty Centre for Therapeutic Brain Intervention. He is the Chief of the General Adult Psychiatry and Health Systems Division at CAMH and is a Professor in the Department of Psychiatry at the University of Toronto. He is the Provincial Clinical Lead for Neurostimulation Procedure for Ontario Health.
His primary area of research focuses on clinical intervention trials of neurostimulation and other novel treatments for depression across the lifespan.
He is the principal or co-investigator on multiple clinical trials using different interventional psychiatry modalities including: psilocybin assisted psychotherapy, IV ketamine, electroconvulsive therapy (ECT), magnetic seizure therapy (MST), repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS).

Autonomic Outflow as a Rapid Read-Out of Brain Stimulation Targets for Anxious Arousal
2026-08-04 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Ryan Webler, MD
Autonomic hyperactivation is a core feature of anxiety-related disorders that is inadequately addressed by current treatment approaches. Localizing autonomic
arousal to a specific brain circuit could inform the development of new treatments.
Here, Dr. Webler presents causal circuit mapping findings showing that focal brain stimulation sites that rapidly modify autonomic arousal map to a convergent brain circuit across stimulation modalities (TMS, DBS, LIFU). In additional independent datasets, modulation of this circuit predicts sustained changes in anxiety-related autonomic hyperactivation. These findings: (1) implicate the autonomic arousal circuit as a potential brain stimulation target for autonomic hyperactivation, and (2) suggest that rapid autonomic arousal changes could potentially serve as a biomarker of sustained autonomic arousal changes.
Key learning objectives include:

Describe how autonomic hyperactivation to anxiogenic stimuli contributes to clinical anxiety, and why it is inadequately addressed by current treatments.
Explain how focal brain stimulation (e.g., TMS, DBS, LIFU) can rapidly modulate autonomic outflow, and how this outflow maps onto a convergent brain circuit for sympathetic arousal.
Evaluate the evidence that the autonomic arousal circuit predicts sustained changes in anxious arousal and identify its potential as a therapeutic target.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, August 7, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - August 4, 2026 at 8:00pm ET | 5:00pm PT
UK- August 5, 2026 at 1:00am BST
Australia- August 5, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Ryan Webler, MD
Dr. Ryan Webler is a postdoctoral research fellow at Harvard Medical School where he uses causal circuit mapping to develop better brain stimulation treatments for anxiety-related disorders. Complementing his research agenda, he is also a postdoctoral clinical fellow at Boston Precision Neurotherapeutics where he implements evidence-based psychotherapeutic protocols to bolster TMS gains.

Transcranial Magnetic Stimulation's Journal Club
2026-08-18 12:00 - 17:00 UTC | Zoom
Transcranial Magnetic Stimulation is the Society's open-access journal and is the first premier journal dedicated to clinical and foundational studies of TMS.
Members of the Research Committee host a quarterly journal club meeting during which published authors of Transcranial Magnetic Stimulation present their research and answer questions from attendees. Participation in the journal club—and access to the journal—is free and open to both Society members and non-members.
Date/Time:

USA - Tuesday, August 18, 2026 at 12:00pm ET
UK - Wednesday, August 18, 2026 at 5pm GMT
Australia - Thursday, August 19, 2026 at 4am AEDT

Zoom Link:
https://us02web.zoom.us/j/81925772026?pwd=[REDACTED]
Webinar ID: 819 2577 2026
Passcode: [REDACTED]
Can't make this date and time? The recording will be available on the CTMSS website.

EEG-guided TMS: the State of the Evidence
2026-09-01 20:00 - 21:00 (America/New_York)
> >Register Now <<
Speaker: Andrew F. Leuchter, MD
Treatments for Major Depressive Disorder (MDD) act at different hierarchical levels of biological complexity, ranging from the individual synapse to the brain as a whole. Evidence suggests that modulation of synchronized electrical activity in brain networks may integrate these different levels of complexity, and may be central to the mechanism of action of repetitive Transcranial Magnetic Stimulation (rTMS). Several lines of research indicate that electroencephalogram (EEG) recording during rTMS can help elucidate the mechanism of action of rTMS treatment. There is emerging evidence that EEG also may be useful in guiding selection of EEG treatment parameters. This presentation will review data on whether EEG guidance of rTMS treatment can improve treatment outcomes for MDD or other neuropsychiatric disorders.
Key learning objectives include:

Discuss the possible role of biomarkers to guide TMS treatment
Understand the rationale for EEG measurement of the effects of EEG treatment
Examine evidence supporting the use of EEG to guide clinical treatment

Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, September 4, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - Sept 1, 2026 at 8:00pm ET | 5:00pm PT
UK- Sept 2, 2026 at 1:00am BST
Australia- Sept 2, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Andrew F. Leuchter, MD
Andrew F. Leuchter, MD, is a Distinguished Professor of Psychiatry and Director of the Neuromodulation Division at UCLA. An expert on the treatment of mood disorders, Dr. Leuchter directs the Transcranial Magnetic Stimulation (TMS) Clinical and Research Service. This is one of the largest academic TMS program in the country and treats patients with depression, OCD, pain, tinnitus, and other neuropsychiatric illness. His research aims to develop novel treatment strategies and predict which treatments are most likely to benefit individual patients.​
Dr. Leuchter has authored over 200 scientific articles on topics including neuromodulation for the treatment of depression, EEG biomarkers to guide treatment of neuropsychiatric illness, and theories of antidepressant action. He teaches internationally on TMS and other neuromodulation methods.

Pain Academy San Diego
2026-10-15

PULSES Providence
2026-10-23 - 2026-10-25
Course Overview
This in-depth training course offers a Certificate of Completion and features lectures and over 3 hours of hands-on training delivered by Clinical TMS Society renowned clinicians, engineers, and researchers, along with special guests. Attendees will receive current, historical, and practical knowledge for treating patients with TMS based on the best available evidence.
The Program Includes:

A review of the clinical studies that serve as the foundation for treatment of TMS for depression, as well as clinically applicable research and current important studies.
Four lectures on the practical administration of TMS for patients, including practice setup to patient dosing, scheduling, and management.
A review of protocols for TMS: high frequency, theta-burst, low frequency, bilateral, alternative brain targets, rescue treatment, and maintenance treatment.
A revised lecture on TMS risks and their prevention and management, including seizure protocol review.
Hands-on training on coil location placement & motor threshold determination with multiple TMS devices.
A review of promising indications beyond depression, including, obsessive compulsive disorder, smoking cessation, migraine, post-traumatic stress disorder, anxiety, and pain.
An extended Q&A Panel with all PULSES faculty and special guests.

Register
